Bibliography
- KLINE NS: Monoamine oxidase inhibitors: an unfinished picaresque tale. In: Discoveries in Biological Psychiatry. Ayd FA Jr (eds). JB Lippincott Company, Philadelphia/Toronto, USA (1970):194-204.
- Physicians’ Desk Reference, Thomson PDR, Montvale, NJ, USA, 2005.
- OWNBY R, GOODNICK PJ: Monoamine oxidase inhibitors. In: Predictors of Treatment Response in Mood Disorders. Goodnick PJ (ed), APPI, Washington/London (1996):37-55.
- SCHOEPP DD, AZZARO AJ: Alteration in dopamine synthesis in rat striatum subsequent to selective type A monoamine oxidase inhibition. J. Neurochem. (1981) 37:527-530.
- MANN JJ, AARONS SF, WILNER PJ et al.: A controlled study of the antidepressant efficacy and side effects of (-)deprenyl, a selective monoamine oxidase inhibitor. Arch. Gen. Psychiatry (1989) 46:45-50.
- MAWHINNEY M, COLE D, AZZARO AJ: Daily transdermal administration of seligiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J. Pharm. Pharmacol. (2003) 55:27-34.
- BODKIN JA, AMSTERDAM JD: Transdermal seligiline in major depression: a double-blind, placebo-controlled, parallel group study in outpatients. Am. J. Psychiatry (2002) 159:1869-1875
- FEIGER AD, RICKELS K, RYNN M, ZIMBROFF DL, ROBINSON DS: Seligiline transdermal system for the treatment of major depressive disorder: an 8 week, double-blind placebo-controlled, flexible-dose trial. J. Clin. Psychiatry In press.
- AMSTERDAM JD, BODKIN JA: Seligiline transdermal system (STS) in the prevention of relapse of major depressive disorder: a 52 week, double-blind, placebo-substitution, parallel group clinical trial. J. Clin. Psychopharmacol. In press.
- AZZARRO AJ, VANDENBERG CM, BLOB LF et al.: Tyramine pressor sensitivity during treatment with the seligiline transdermal system 6 mg/24 hour in healthy subjects. J. Clin. Psychopharmacol. (2006) 46:933-944.
- ROBINSON DS, AMSTERDAM J: Safety and tolerability of the seligiline transdermal system 20 mg for treatment of major depressive disorder. American College of Neuropsychopharmacology (ACNP) Annual Meeting. Hawaii (11 – 15 December 2005).
- AZZARRO AJ, ZIEMNIAK JA, KEMPER EM, CAMPBELL BJ, VANDENBERG CM: Studies on the potential for pharmacokinetic drug interactions between seligiline transdermal system 6 mg/24 hour and three psychotropic medications metabolized by hepatic cytochrome P450 enzymes. American Psychiatric Association Annual Meeting. Toronto, Canada (20 – 25 May 2006).
- AZZARRO AJ et al.: Pressor effects of oral tyramine and OTC sympathomimetic amines following steady-state transdermal administration of selegiline to healthy volunteers. Poster at American College of Neuropsychopharmacology (ACNP) Annual Meeting. San Juan, PR (8 – 12 December 2000.
- SHULMAN KI, WALKER SE: A reevaluation of dietary restrictions for irreversible monoamine oxidase inhibitors. Psychiatr. Ann. (2001) 31:378-384.
- SHULMAN KI, WALKER SE, MACKENZIE S, KNOWLES S: Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J. Clin. Psychopharmacol. (1989) 9(6):397-402.